エドガーで原本を確認する
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 2, 2025
IQVIA HOLDINGS INC.
(Exact name of registrant as specified in its charter)
| Delaware | 001-35907 | 27-1341991 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| 2400 Ellis Rd., |
| Durham, North Carolina 27703 |
| (Address of principal executive offices) |
Registrant’s telephone number, including area code: (919) 998-2000
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class |
Trading Symbol |
Name of Each Exchange on which Registered |
||
| Common Stock, par value $0.01 per share | “IQV” | New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Appointment of Michael J. Fedock as Executive Vice President and Chief Financial Officer, Effective February 28, 2026
On September 2, 2025, IQVIA Holdings Inc. (the “Company”) announced that Michael J. Fedock will succeed Ronald E. Bruehlman as Executive Vice President and Chief Financial Officer (“CFO”), effective February 28, 2026. This transition is part of the Company’s previously announced Chief Financial Officer succession plan.
Mr. Fedock, age 50, has more than 25 years of experience in the healthcare industry. He joined the Company in 2016, most recently serving as Senior Vice President, Financial Planning and Analysis since April 2021. From July 2019 to April 2021, Mr. Fedock served as the CFO for the Company’s Research & Development Solutions Business Unit and from May 2016 to July 2019, he served as CFO of IQVIA Laboratories (formally known as Q2 Solutions, a joint venture between the Company and Quest Diagnostics Incorporated and a leading clinical trial laboratory services organization). Prior to joining IQVIA Laboratories, Mr. Fedock spent 13 years with ICON plc where he held various roles of increasing responsibility in both financial and operational leadership positions.
In connection with Mr. Fedock’s promotion, effective February 28, 2026, his annual base salary will increase to $750,000, with an annual cash incentive target of 100% of his base salary, subject to the terms and conditions of the Company’s annual incentive program. Mr. Fedock will be eligible to participate in annual Long Term Incentive cycles subject to the terms and conditions of the Company’s 2017 Incentive and Stock Award Plan and in the Company’s standard benefit plans in the U.S. available to executives at his level in accordance with their terms.
Transition of Ronald E. Bruehlman to the role of Senior Advisor to the CEO, Effective February 28, 2026
On the same date, the Company announced that Mr. Bruehlman will retire, effective February 28, 2026, from his current role as Executive Vice President and Chief Financial Officer and transition to Senior Advisor to the CEO, ensuring continuity and a seamless transition.
| Item 7.01. | Regulation FD Disclosure. |
On September 2, 2025, the Company issued a press release announcing Mr. Fedock’s appointment and Mr. Bruehlman’s transition to a senior advisor role, which is attached hereto as Exhibit 99.1.
| Item 9.01. | Financial Statements and Exhibits. |
| Exhibit No. |
Description |
|
| 99.1 | Press release dated September 2, 2025 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: September 2, 2025
| IQVIA HOLDINGS INC. | ||
| By: | /s/ Eric M. Sherbet |
|
| Eric M. Sherbet | ||
| Executive Vice President, General Counsel and Secretary |
||
Exhibit 99.1
News Release
| Contact: | Kerri Joseph, IQVIA Investor Relations (kerri.joseph@iqvia.com) +1.973.541.3558 |
|
| Alissa Maupin, IQVIA Media Relations (alissa.maupin1@iqvia.com) +1.919.923.6785 |
||
IQVIA Announces CFO Transition in Early 2026
Ron Bruehlman to become Senior Advisor to CEO; Michael Fedock Named as New CFO
RESEARCH TRIANGLE PARK, N.C. — (BUSINESS WIRE) — IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences and healthcare industries, today announced a planned leadership transition in its finance organization. Michael Fedock, currently Senior Vice President of Financial Planning & Analysis, has been appointed Executive Vice President and Chief Financial Officer, effective February 28, 2026. He will succeed Ron Bruehlman, who will retire as CFO after a distinguished tenure. Mr. Bruehlman will continue to serve as Senior Advisor to Chief Executive Officer Ari Bousbib, ensuring continuity and a seamless transition.
“Ron has been a cornerstone of IQVIA’s transformation and growth,” said Ari Bousbib. “His strategic leadership and financial stewardship have helped position IQVIA as a global leader. I am grateful for his continued support during this transition.”
Mr. Bruehlman’s career with IQVIA started in 2011 when he joined IMS Health as CFO. He was instrumental in the Initial Public Offering of IMS Health in 2014 and the successful merger of Quintiles and IMS Health in 2016. He returned from retirement in 2020 to support IQVIA during a critical period, including navigating the COVID-19 pandemic and building a high-performing global finance organization.
Mr. Bousbib added, “This transition has been thoughtfully planned. Mike brings deep industry experience, strong financial expertise, a proven track record within IQVIA and several years of close collaboration with me and the IQVIA senior leadership team. He is exceptionally well-prepared to lead our finance organization and support our long-term growth strategy.”
Mr. Fedock joined IQVIA in 2016 and has held several senior financial roles, including CFO of IQVIA’s Research & Development Solutions business unit and CFO of IQVIA Laboratories (formerly known as Q2 Solutions, the company’s joint venture with Quest Diagnostics). Prior to joining IQVIA, he served in various leadership roles at ICON plc and other healthcare organizations, with experience spanning both pharmaceutical and hospital settings. Mr. Fedock holds a Master of Business Administration from the University of Baltimore and a Bachelor of Science in Biological Sciences from Drexel University.
“It is a privilege to take on the role of CFO at IQVIA,” said Mr. Fedock. “I have worked closely with Ron for nearly a decade, and I greatly appreciate his mentorship and support. I look forward to continuing to work with Ari as we drive IQVIA’s strategic growth and shareholder value creation.”
“It has been an honor to serve as CFO of the world-class organization IQVIA has become,” said Mr. Bruehlman. “I look forward to supporting Ari, Mike and the rest of the IQVIA leadership team during this transition and beyond as IQVIA continues to execute on its long-term strategy.”
1
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI®, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 90,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.
# # #
2